ABBV Stock Overview AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for AbbVie Historical stock prices Current Share Price US$174.20 52 Week High US$191.82 52 Week Low US$143.00 Beta 0.56 1 Month Change -0.18% 3 Month Change -1.15% 1 Year Change 17.94% 3 Year Change 44.83% 5 Year Change 114.53% Change since IPO 108.27%
Recent News & Updates
Third quarter dividend of US$1.64 announced Dec 30
AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million. Dec 13 AbbVie Inc. (NYSE:ABBV) complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures. Dec 11
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab Dec 09
New minor risk - Share price stability Nov 22 See more updates
Third quarter dividend of US$1.64 announced Dec 30
AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million. Dec 13 AbbVie Inc. (NYSE:ABBV) complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures. Dec 11
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab Dec 09
New minor risk - Share price stability Nov 22
Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer Nov 19
Third quarter dividend of US$1.64 announced Nov 17
Investor sentiment deteriorates as stock falls 16% Nov 16
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia Nov 12
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025 Nov 02
Third quarter 2024 earnings released: EPS: US$0.88 (vs US$1.00 in 3Q 2023) Nov 01 AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion. Oct 28
U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease Oct 17
Upcoming dividend of US$1.55 per share Oct 08
Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing Oct 03
AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 01
Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer Sep 28
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management Sep 18
Second quarter dividend of US$1.55 announced Sep 16
AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia Sep 05 Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Aug 20
AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process Aug 15
Executive Chairman recently sold €11m worth of stock Aug 08 AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others. Aug 02
New minor risk - Profit margin trend Jul 26
Second quarter 2024 earnings released: EPS: US$0.77 (vs US$1.14 in 2Q 2023) Jul 26
AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis Jul 26 AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency Jul 24
Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer Jul 10
Upcoming dividend of US$1.55 per share Jul 08 AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024 Jul 04
AbbVie Announces Board Changes Jul 01
AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma Jun 27 AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) Jun 25
First quarter dividend of US$1.55 announced Jun 24 AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024 Jun 21
AbbVie Inc. Announces Board of Directors Changes Jun 20
AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer Jun 08
AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis May 31 AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders. May 24
Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults May 09
Abbvie Inc. Announces Board Changes, Effective July 1, 2024 Apr 28
First quarter 2024 earnings released: EPS: US$0.77 (vs US$0.13 in 1Q 2023) Apr 26
AbbVie Inc. Announces Positive Topline Results from Level Up Apr 26 Shareholder Returns ABBV AT Biotechs AT Market 7D 3.1% 2.4% 1.4% 1Y 17.9% 12.1% -0.4%
See full shareholder returns
Return vs Market: ABBV exceeded the Austrian Market which returned -1.1% over the past year.
Price Volatility Is ABBV's price volatile compared to industry and market? ABBV volatility ABBV Average Weekly Movement 4.8% Biotechs Industry Average Movement 7.7% Market Average Movement 3.7% 10% most volatile stocks in AT Market 6.3% 10% least volatile stocks in AT Market 2.3%
Stable Share Price: ABBV's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: ABBV's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
Show more AbbVie Inc. Fundamentals Summary How do AbbVie's earnings and revenue compare to its market cap? ABBV fundamental statistics Market cap €306.17b Earnings (TTM ) €4.95b Revenue (TTM ) €54.14b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ABBV income statement (TTM ) Revenue US$55.53b Cost of Revenue US$16.47b Gross Profit US$39.06b Other Expenses US$33.98b Earnings US$5.08b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 2.88 Gross Margin 70.33% Net Profit Margin 9.15% Debt/Equity Ratio 1,174.8%
How did ABBV perform over the long term?
See historical performance and comparison Dividends
3.7% Current Dividend Yield When do you need to buy ABBV by to receive an upcoming dividend? AbbVie dividend dates Ex Dividend Date Jan 15 2025 Dividend Pay Date Feb 14 2025 Days until Ex dividend 12 days Days until Dividend pay date 42 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 07:40 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources AbbVie Inc. is covered by 54 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Toung Argus Research Company Ishan Majumdar Baptista Research Luisa Hector Berenberg
Show 51 more analysts 
